AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3391875 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterotablet B 500 mg (multiple dosing)
Number of subjects: 29
Study 3391875 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 + 800 mg
Number of subjects: 29
Study 29363287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID)
Number of subjects: 235
Study 29363287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg once daily (LOR BID + PHEN QD)
Number of subjects: 235
Study 29363287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg twice daily (LOR BID + PHEN BID)
Number of subjects: 235
Study 27353237 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary, transcutaneous, pharmaceutical SGB with lidocaine
Number of subjects: 36
Study 27353237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23732265 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management (group 2)
Number of subjects: 132
Study 23732265 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization management (group 1)
Number of subjects: 132
Study 23788832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits (up to three visits including risk assessment, home counseling intervention, and a booster session)
Number of subjects: 230
Study 23788832 — intervention group
Group type: COMPARATOR
Intervention: No preventive home visits (Control group)
Number of subjects: 230
Study 20839435 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial group (remnant ACL)
Number of subjects: 97
Study 20839435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remnant ACL)
Number of subjects: 97
Study 17825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin closure by staples with closure of subcutaneous space
Number of subjects: 153
Study 17825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin closure by staples with non-closure of subcutaneous space
Number of subjects: 153
Study 17825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suture with closure of subcutaneous space
Number of subjects: 153
Study 17825472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous suture with non-closure of subcutaneous space
Number of subjects: 153
Study 16389216 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (18, 36, 54, or 72 mg once daily)
Number of subjects: 220
Study 16389216 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 220
Study 16389216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 16389216 — intervention group
Group type: COMPARATOR
Intervention: OROS methylphenidate and Placebo
Number of subjects: 220
Study 12930332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power 50-ms 1064 Nd:YAG laser treatment
Number of subjects: 10
Study 11293738 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mcg/kg) administered intravenously within 1 hour of surgery and every 12 hours thereafter, switched to enteral captopril (3 mg/kg/day) every 8 hours when tolerating feeds.
Number of subjects: 36
Study 11293738 — intervention group
Group type: COMPARATOR
Intervention: No angiotensin converting enzyme inhibitors administered (Control group).
Number of subjects: 36
Study 9226707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (Group A)
Number of subjects: 60
Study 9226707 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 60
Study 8433561 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with dextrose infusion
Number of subjects: 10
Study 8433561 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine infusion
Number of subjects: 10
Study 8433561 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion with insulin and glucose
Number of subjects: 10
Study 8433561 — intervention group
Group type: COMPARATOR
Intervention: Fasting without intervention
Number of subjects: 10
Study 3303247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 0
Study 3303247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3303247 — intervention group
Group type: COMPARATOR
Intervention: Non-administered group
Number of subjects: 0
Study 31690117 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker™ device
Number of subjects: 117
Study 31690117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (device with projections removed)
Number of subjects: 117
Study 31690117 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 30479287 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 49
Study 30479287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27683967 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy for complicated grief (CG) treatment
Number of subjects: 151
Study 26577943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home group (oral amoxicillin treatment at home)
Number of subjects: 1118
Study 26577943 — intervention group
Group type: COMPARATOR
Intervention: Hospital group (oral amoxicillin treatment in hospital for first 48 hours)
Number of subjects: 1118
Study 26577943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home group
Number of subjects: 1118
Study 26577943 — intervention group
Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 1118
Study 24244656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (3 times a week for 12 weeks, aerobic exercise at 55‐75% maximum heart rate for 60 min, resistance exercise with barbells 1‐3 kg and resistance bands)
Number of subjects: 20
Study 24244656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 20
Study 24244656 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (Control group)
Number of subjects: 20
Study 21124314 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-619
Number of subjects: 0
Study 19034749 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 to 120 mg QD, titrated based on response, with 90 mg QD as an intermediate dose)
Number of subjects: 249
Study 19034749 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 249
Study 17162316 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine qd plus efavirenz qd (QD arm)
Number of subjects: 36
Study 17162316 — intervention group
Group type: COMPARATOR
Intervention: Abacavir/lamivudine/zidovudine bid plus efavirenz qd (BID arm)
Number of subjects: 36
Study 12667566 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy after VT
Number of subjects: 449
Study 12667566 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy after VF
Number of subjects: 449
Study 11108507 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin levels
Number of subjects: 0
Study 11108507 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant levels
Number of subjects: 0
Study 11108507 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtherapeutic levels
Number of subjects: 0
Study 11108507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic factors
Number of subjects: 0
Study 11108507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic factors
Number of subjects: 0
Study 9183334 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA and heparin therapy
Number of subjects: 3924
Study 30635271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab followed by ipilimumab (nivo/ipi)
Number of subjects: 113
Study 30635271 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab followed by nivolumab (ipi/nivo)
Number of subjects: 113
Study 30007160 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 0.1 mg
Number of subjects: 123
Study 30007160 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg
Number of subjects: 123
Study 30007160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 30007160 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (both doses)
Number of subjects: 123
Study 30007160 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 123
Study 27543458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (ECs) containing 2.4%, 1.8% or 0% nicotine
Number of subjects: 0
Study 27543458 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (ECs)
Number of subjects: 0
Study 24299276 — intervention group
Group type: EXPERIMENTAL
Intervention: Poison prevention video module
Number of subjects: 297
Study 24299276 — intervention group
Group type: COMPARATOR
Intervention: Usual class curriculum (control)
Number of subjects: 297
Study 22573644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (10-20 mg/d)
Number of subjects: 2636
Study 18302459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax appliance and reverse headgear (UCLP group)
Number of subjects: 36
Study 18302459 — intervention group
Group type: COMPARATOR
Intervention: Hyrax appliance and reverse headgear (noncleft group)
Number of subjects: 36
Study 18302459 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 36
Study 16442264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique using nitrous oxide/oxygen and intravenous Midazolam
Number of subjects: 0
Study 12897376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin measurement
Number of subjects: 321
Study 12897376 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 321
Study 10907363 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (enarenal)
Number of subjects: 20
Study 10907363 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9431825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meal (ethanol consumed after meal)
Number of subjects: 9
Study 9431825 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich meal (ethanol consumed after meal)
Number of subjects: 9
Study 9431825 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal (ethanol consumed after meal)
Number of subjects: 9
Study 9431825 — intervention group
Group type: COMPARATOR
Intervention: Fasting (ethanol consumed on an empty stomach)
Number of subjects: 9
Study 9431825 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion (ethanol administered by i.v. infusion)
Number of subjects: 9
Study 8277056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental digital radiology
Number of subjects: 0
Study 3029792 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (1.2% THC)
Number of subjects: 12
Study 3029792 — intervention group
Group type: COMPARATOR
Intervention: Cannabinoid-exhausted marijuana (placebo)
Number of subjects: 12
Study 29729702 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Flaccidity Compound (KFC) for 1.5 months
Number of subjects: 0
Study 29729702 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Flaccidity Compound (KFC) for 3 months
Number of subjects: 0
Study 29729702 — intervention group
Group type: COMPARATOR
Intervention: Kidney Flaccidity Compound (KFC)
Number of subjects: 0
Study 27780109 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (n=43)
Number of subjects: 85
Study 27780109 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise (n=42)
Number of subjects: 85
Study 27780109 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 85
Study 25710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 168
Study 25710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 168
Study 25710119 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 168
Study 23885616 — intervention group
Group type: EXPERIMENTAL
Intervention: Round-sharp needle of new nine-needle
Number of subjects: 80
Study 23885616 — intervention group
Group type: COMPARATOR
Intervention: Elongated needle treatment
Number of subjects: 80
Study 20629511 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic approaches to treatment response including detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes, and differential gene-expression patterns.
Number of subjects: 0
Study 20629511 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic approaches to treatment response
Number of subjects: 0
Study 19056701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Aclasta ‐ Novartis)
Number of subjects: 0
Study 17062711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate model for evaluating skeletal events
Number of subjects: 0
Study 17062711 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple methods of analysis
Number of subjects: 0
Study 17062711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate approach
Number of subjects: 0
Study 12612867 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 589
Study 12612867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 10801170 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade (MAB)
Number of subjects: 8275
Study 10801170 — intervention group
Group type: COMPARATOR
Intervention: Androgen suppression (AS) alone
Number of subjects: 8275
Study 10801170 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (part of MAB)
Number of subjects: 8275
Study 10801170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide and flutamide (part of MAB)
Number of subjects: 8275
Study 9200137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal cigarette exposure
Number of subjects: 131
Study 9200137 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal secondhand smoke exposure
Number of subjects: 131
Study 9200137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal marijuana exposure
Number of subjects: 131
Study 9200137 — intervention group
Group type: COMPARATOR
Intervention: Maternal prenatal passive smoke exposure
Number of subjects: 131
Study 1376839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release formulation of isradipine (Im) at 5 mg once daily
Number of subjects: 380
Study 1376839 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of isradipine (Is) at 2.5 mg twice daily
Number of subjects: 380
Study 1376839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release formulation of isradipine (Im)
Number of subjects: 380
Study 1376839 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation of isradipine (Is)
Number of subjects: 380
Study 2864027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (16-week program emphasizing reflective problem-solving strategies and social problem-solving skills)
Number of subjects: 0
Study 2864027 — intervention group
Group type: COMPARATOR
Intervention: Attention control treatment
Number of subjects: 0
Study 2864027 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 0
Study 31726876 — intervention group
Group type: EXPERIMENTAL
Intervention: G-estimation method for treatment on the outcome (physical activity)
Number of subjects: 0
Study 31726876 — intervention group
Group type: EXPERIMENTAL
Intervention: G-estimation method
Number of subjects: 0
Study 29946655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified scene simulation teaching method
Number of subjects: 40
Study 29946655 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 40
Study 28793896 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8968 300 mg subcutaneously every 4 weeks (600 mg intravenous loading dose) for 52 weeks
Number of subjects: 324
Study 28793896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 28793896 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8968 300 mg
Number of subjects: 324
Study 28793896 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8968 and Placebo
Number of subjects: 324
Study 26589192 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio-Taping (K-Tape)
Number of subjects: 60
Study 26589192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24294677 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR forms
Number of subjects: 20
Study 24294677 — intervention group
Group type: COMPARATOR
Intervention: Control cases (no SBAR forms)
Number of subjects: 20
Study 24294677 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR cases
Number of subjects: 20
Study 21426232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg every 12 hours for 6 months (n=50)
Number of subjects: 100
Study 21426232 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours for 6 months (n=50)
Number of subjects: 100
Study 18279183 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 92
Study 18279183 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus azithromycin
Number of subjects: 92
Study 18279183 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus metronidazole
Number of subjects: 92
Study 18279183 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus sub-antimicrobial dose of doxycycline
Number of subjects: 92
Study 17262127 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv gel + SRP
Number of subjects: 45
Study 17262127 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel + SRP
Number of subjects: 45
Study 17262127 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 45
Study 12527536 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional adaptation skills training (FAST) group therapy program (24 sessions)
Number of subjects: 40
Study 12527536 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 40
Study 10770538 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day)
Number of subjects: 103
Study 10770538 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day) plus indinavir (IND; 800 mg q8h)
Number of subjects: 103
Study 9581003 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician intervention
Number of subjects: 175
Study 9581003 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Number of subjects: 175
Study 9581003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 175
Study 9581003 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 175
Study 8443934 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg twice daily
Number of subjects: 23
Study 8443934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3098131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 100
Study 3098131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30962688 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 0
Study 30962688 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 0
Study 28264663 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine counselling plus additional problem-solving for caregivers
Number of subjects: 58
Study 28264663 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling alone
Number of subjects: 58
Study 25869157 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18
Study 25869157 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 18
Study 23953322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.227 mg/kg for ED50; 0.283 mg/kg for ED95)
Number of subjects: 50
Study 23953322 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 50
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 12 mg
Number of subjects: 0
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg
Number of subjects: 0
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 24 mg
Number of subjects: 0
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg
Number of subjects: 0
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 8 mg
Number of subjects: 0
Study 20560900 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 16 mg
Number of subjects: 0
Study 19208045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile-only stimulation
Number of subjects: 40
Study 19208045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory intervention (auditory, tactile, visual, and vestibular)
Number of subjects: 40
Study 19208045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 40
Study 17869975 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (50 mg/d after a 70-mg loading dose)
Number of subjects: 224
Study 17869975 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.6-1.0 mg/kg per day)
Number of subjects: 224
Study 17869975 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 224
Study 17869975 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 224
Study 17869975 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin and Amphotericin B
Number of subjects: 224
Study 15491237 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI survey self‐administered through an Internet browser using a touchscreen
Number of subjects: 90
Study 15491237 — intervention group
Group type: COMPARATOR
Intervention: In-person interview
Number of subjects: 90
Study 11505696 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft type margarine (30 g total per day, 15 g twice a day)
Number of subjects: 83